GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Zydus Lifesciences Ltd

Zydus Lifesciences receives USFDA approval for Dapagliflozin 5mg/10mg tablets

ORDERS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 08 Apr 2026, 09:47 AM IST  ·  BSE ID: a85f9a18-ad1f-4b66-8ef5-a0361094014a
View Original BSE Filing (PDF)
💡
In Simple Terms
Zydus got approval to sell a diabetes medication in the US, qualifying for 6 months of market protection before competitors can copy it.
🤖 AI Summary
  • Zydus receives final USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • 180 days of shared generic drug exclusivity awarded with this approval
  • Manufacturing at group's SEZ Ahmedabad formulation facility
  • Dapagliflozin achieved USD 10.2bn annual US sales as of February 2026
  • 436th USFDA approval for Zydus; 505 ANDAs filed since FY 2003-04
🔢 Key Numbers — exact figures from BSE filing, not rounded
USFDA approvals held
436
ANDAs filed cumulatively
505
Dapagliflozin annual US sales
USD 10.2bn
Shared generic exclusivity period
180 days
🏢 How This Affects the Company
📈
Business Impact
Approval expands Zydus's generic portfolio in the USD 10.2bn US dapagliflozin market. 180-day exclusivity provides first-mover advantage in the generic segment, enabling revenue capture ahead of additional competitors.
💰
Financial Impact
Generic dapagliflozin sales will flow through the formulation segment. The exclusivity period positions the company to capture disproportionate volumes and pricing in early market phase before full generic competition.
⚙️
Operational Impact
Production capacity leveraged at existing SEZ Ahmedabad facility — no new capex signalled. Manufacturing utilization increases on established infrastructure.
⚠️
Risk Impact
Market exclusivity duration (180 days) is fixed and short. Sales dependent on pricing environment and market uptake in a competitive diabetes therapeutics category.
👥 What This Means For Shareholders
✅
Action Required
No immediate action required. Monitor next quarterly results for dapagliflozin revenue contribution and exclusivity impact.
👤
Who Is Affected
All Zydus shareholders benefit from expanded US generic portfolio and exclusivity-period revenue uplift. Impact materialises in FY26-27 earnings as product ramps.
🔍
Management Signal
Approval demonstrates Zydus's execution capability in high-value generic filings and commitment to building scale in diabetes therapeutics, a key chronic care segment.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q4 FY26 / Q1 FY27 results — track dapagliflozin revenue contribution and exclusivity period impact
October 2026 — 180-day exclusivity expiration; monitor competitive generic entrants announcement
Management guidance on diabetes franchise revenue trajectory in upcoming calls
MEDIUM RISK Short 180-day exclusivity window limits pricing power. No manufacturing capacity or ramp details disclosed. Competitive generic entry post-exclusivity assumed.
💡 Investor Takeaway
Zydus secured USFDA approval for Dapagliflozin in a USD 10.2bn annual US market. Exclusive 180-day generic window enables first-mover revenue, expiring mid-October 2026. Filing confirms 436 cumulative approvals and 505 ANDAs filed since FY 2003-04.
⚖️ Strengths & Concerns

✅ Positives

  • Market size of USD 10.2bn in US validates scale opportunity for generic dapagliflozin franchise
  • 180-day exclusivity provides defined market advantage window before full generic competition emerges

⚠️ Concerns

  • Exclusivity period of 180 days is relatively short; market opens to other generics within 6 months
  • Filing provides no details on pricing, market entry timeline, or manufacturing capacity committed
📅 Company Track Record
Zydus's 436 USFDA approvals reflect consistent filing execution since FY 2003-04. On 14-Mar-2026, Zydus licensed Desidustat to China Medical System for NMPA approval, unlocking royalties in the 120-million-patient Chinese CKD market, demonstrating diversified geography and indication expansion.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.